The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2017

Filed:

Jan. 29, 2014
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Carolyn Michele Cammarano, West Caldwell, NJ (US);

Matthew P. Christopher, Brookline, MA (US);

Christopher Dinsmore, Newton, MA (US);

Ronald J. Doll, Convent Station, NJ (US);

Francesc Xavier Fradera Llinas, Brookline, MA (US);

Chaomin Li, Boston, MA (US);

Michelle Machacek, Brookline, MA (US);

Michelle Martinez, Watertown, MA (US);

Latha G. Nair, Edison, NJ (US);

Weidong Pan, Somerset, NJ (US);

Michael Hale Reutershan, Brighton, MA (US);

Manami Shizuka, Lexington, MA (US);

Dietrich P. Steinhuebel, Boston, MA (US);

Binyuan Sun, Boston, MA (US);

Christopher Francis Thompson, Arlington, MA (US);

B. Wesley Trotter, Medfield, MA (US);

Yaolin Wang, Short Hills, NJ (US);

Liping Yang, Arlington, MA (US);

Stephane L. Bogen, Somerset, NJ (US);

Matthew E. Voss, Ville De West, SG;

Jagannath Panda, Singapore Science Park II, SG;

Anthappan Tony Kurissery, Singapore Science Park II, SG;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/52 (2006.01); C07D 473/16 (2006.01); C07D 473/00 (2006.01); C07D 473/34 (2006.01); C07D 473/30 (2006.01);
U.S. Cl.
CPC ...
C07D 473/00 (2013.01); C07D 473/16 (2013.01); C07D 473/30 (2013.01); C07D 473/34 (2013.01);
Abstract

The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.


Find Patent Forward Citations

Loading…